Forcyte has been selected as 1 of 8 companies given a presentation space at the Society of Laboratory Automation and Screening annual meeting in Washington D.C. on Feb 4-6. We will be showcasing our functional contractility assay technology, discussing ideas, seeking collaboration opportunities and learning about other evolving fields and challenges. Come by our booth! 1737C!
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on uterine contractility that will enable deeper functional studies on reproductive disorders.
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on vasodilation triggers of migraine pain that will enable rapid phenotypic screening for cranial vasoprotectors.
We are seeking a razor-sharp and self-driven ‘A-player’ trained in and stimulated by biotechnology to join the founding team and lead operations in our LA Biomed location! Great opportunity to become a part of something special early on and grow with the company. Let your colleagues know! Link to job ad: https://forcytebio.com/wp-content/uploads/2018/03/Associate-Bioengineer-short.pdf Get in touch directly to apply — email@example.com
>3 years of work and development in the Di Carlo Lab has led to a thorough publication describing the broad capabilities and use-cases for the FLECS platform. On February 8, 2018, our paper “Elastomeric sensor surfaces for high-throughput single-cell force cytometry” was published online in Nature Biomedical Engineering! Link: https://www.nature.com/articles/s41551-018-0193-2 Thanks to all who contributed – this marks the beginning of an exciting journey to improving health care!
Dr. Pushkarsky presented the team’s overall work on FLECS Technology at the annual SBI2 meeting in San Diego back in September 2017. He was happy to have been awarded the Presidential Innovation Award and invited to write a short piece about his presentation – last month, this piece was published in the journal ASSAY and Drug Development Technologies! Link to article is here: https://www.ncbi.nlm.nih.gov/pubmed/29266960
We’re excited to be attending the 2018 San Francisco edition of the RESI Series on January 9th, 2018! Dr. Pushkarsky will be on the floor sharing our technology and seeking interactions with potential investors and collaborators. Feel free to reach out via the Contact Form if you would like to meet up!